A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus

Exclusion Criteria

• •History of cancer except basal cell carcinoma treated with apparent success with curative therapy \>=1 year before randomization into the study
• •Evidence of active or latent tuberculosis (TB)
• •History of primary immunodeficiency
• •Evidence of infection at any time with hepatitis B or C virus or human immunodeficiency virus (HIV)-1 or HIV-2, or active infection with hepatitis A, as determined by results of testing at Screening
• •History of sepsis or serious, recurrent, chronic infection, current signs and symptoms of clinically significant chronic infection, or recent (within 6 months before Baseline visit) serious infection
• •Any history or evidence of opportunistic infection within 6 months of Screening including severe cytomegalovirus (CMV) or herpetic infections (such as disseminated herpes, herpes encephalitis, ophthalmic herpes)
• •Receipt of cyclophosphamide (intravenous or oral) within 6 months of Screening
• •Have any absolute contraindications to skin punch biopsies, for example, a history of coagulation disorders.